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Summary A phase II trial was performed to evaluate the efficacy and tolerance of vinorelbine (VNB),
mitomycin C (MMC), and recombinant human granulocyte colony-stimulating factor (G-CSF) in advanced
breast cancer. Between October 1992 and July 1994, 55 patients entered this trial. Nine patients had locally
advanced disease and 46 had distant metastases, including 14 who had received previous palliative chemotherapy
with (n =9) or without anthracyclines (n = 5). Therapy consisted ofVNB 40 -50 mg m-2 diluted in 250 ml saline
infused over 30 min every 3 weeks, and MMC 15 mg m-2 administered by intravenous bolus injection every 6
weeks. G-CSF was given at 5 pg kg-' day-' subcutaneously from days 2 to 7 following each cytotoxic drug
administration. Treatment was continued in case of response or stable disease for a total of six courses. The
overall response rate was 73% for all 55 patients (95% confidence interval, 59-84%), including 12 (22%)
complete response (CR) and 28 (51%) partial response (PR); 13 patients (24%) had stable disease (SD), and only
two (4%) progressed. All nine patients with locally advanced disease were rated responsive (two pCR, seven PR)
and underwent surgery with curative intent. Eight out of nine remain disease free after a median observation
period of 18 months (range, 13.5-28 months). Among the 32 previously untreated patients with metastatic
disease, nine (28%) achieved CR, 15 PR (47%), seven SD (22%) and one PD (3%). Second-line chemotherapy
with this regimen resulted in 7/14 (50%) objective remissions (one CR, six PR), six had SD and one PD. The
median time to progression was 12 months (range, 2-24+months) in previously untreated patients with
disseminated disease, and 6.0 months (range, 2 -22 months) in those who had failed prior chemotherapy. After a
median follow-up time of 20 months, 24 patients with distant metastases are still alive with disease; median
survival has not been reached yet. The dose-limiting toxicity was myelosuppression: six (11%) and ten patients
(18%) had World Health Organization grade 3, and eight (14%) and nine patients (16%) had grade 4 leucopenia
and granulocytopenia respectively. Severe (WHO grade 3) non-haematological toxicities included nausea/
vomiting in 7%, constipation in 9%, peripheral neuropathy in 5%, infectious episodes in 7%, phlebitis due to
drug extravasation in 5%, alopecia in 9%, and acute reversible pulmonary toxicity in 11%. Our data suggest that
vinorelbine, mitomycin C plus G-CSF has an excellent anti-tumour activity in advanced breast cancer, probably
superior to most other available combination chemotherapy regimens. This combination does not seem to
present significant cross-resistance with previous CMF or anthracycline regimens. Apart from reversible, acute
pulmonary toxicity, a rare adverse reaction that had previously been described for VNB, as well as the
combination ofnatural vinca alkaloids with mitomycin C, and few episodes ofgrade 3 neurotoxicity (all ofwhich
occurred at the initial 50 mg m 2 VNB dose level), the tolerance of this regimen seems acceptable and justifies
further evaluation in front-line and salvage therapy of advanced breast cancer.
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Breast cancer is the most common malignancy affecting
women in the western world. In Europe, the annual incidence
rate is approximately 80 new cases per 100 000 women.
Despite adequate primary surgical treatment, with or without
post-operative radiation therapy, 25-30% of patients with
negative axillary lymph nodes, and more than two-thirds of
those with axillary node involvement at the time of diagnosis
will have recurrent and/or metastatic breast cancer within a
decade following surgery, and will subsequently die of the
disease (Valagusa, 1978; Bonadonna et al., 1995). Conven-
tional combination chemotherapy has not been able to
change the natural history of advanced breast cancer and
current treatment approaches seem to have reached their
maximum efficacy. Therefore, the identification of new active
agents and/or drug combinations with a superior therapeutic
index remains a principal goal of investigational efforts. At
present, the most promising new cytotoxic agents under
clinical evaluation in breast cancer are the taxanes and
vinorelbine. Taxanes inhibit mitosis through a stabilisation of
microtubules and have produced a response rate of more
than 50% in advanced breast cancer patients even if they
have failed first-line chemotherapy (Holmes et.,al., 1991;
Reichmann et al., 1993; Chevallier et al., 1995). However,
taxanes are expensive and induce important clinical toxicities,
such as dose-dependent granulocytopenia, myalgias and
neuropathies (Rowinsky et al., 1990). The second promising
new agent, vinorelbine (5'-nor-anhydrovinblastine), is a semi-
synthetic vinca alkaloid, which differs from vinblastine by the
presence of an eight-member catharanthine ring instead of a
nine-member ring (Mangeney et al., 1979). The target,
however, remains cytosolic tubulin, a ubiquitous eukaryotic
protein. Vinorelbine seems to disorganise microtubules of the
mitotic figure at a lower concentration than other vinca
alkaloids and one at which it fails to affect the axonal
microtubules (Binet et al., 1990). These observations led to
the suggestion that vinorelbine might be less neurotoxic and
more toxic to the cancer cell. During the past 5 years, this
drug has undergone clinical evaluation in a number of
malignancies (Sorensen, 1995). In advanced breast cancer,
several independent phase II trials of first-line chemotherapy
with vinorelbine yielded an overall response rate of 37-60%
and an overall complete remission rate of 2-16%
(Cannabbio et al., 1989; Garcia-Conde et al., 1992; Romero
et al., 1994; Toussaint et al., 1994; Fumoleau et al., 1994). In
all of these studies, treatment was well tolerated, with
neutropenia being the most frequent and dose-limiting
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toxicity. Based on these results and documented activity of
single-agent vinorelbine in second-line chemotherapy (Gas-
parini et al., 1994; Degardin et al., 1994), a substantial
activity for combination regimens including this agent would
be anticipated, and preliminary results seem to confirm these
expectations (Spielmann et al., 1994; Fabi et al., 1995; Nole
et al., 1995).
In a previous phase II study in patients with advanced
refractory disease, we have established the feasibility, activity
and tolerance of the in vitro synergistic combination of
vinorelbine and mitomycin C (Scheithauer et al., 1993).
Because myelosuppression constitutes the dose-limiting
toxicity of both agents when given alone or in combination,
and the use of a supportive cytokine may allow administra-
tion of higher, potentially more effective drug concentrations,
the present phase II study in patients with advanced breast
cancer has been initiated. On account of the modest
myelosuppressive potential of conventional dose vinorelbine
(30 mg m-2) plus mitomycin C, with granulocyte recovery
usually within 7-10 days (as assessed in our previous trial),
we have decided to use short, i.e. 5 day courses of G-CSF
support.
Patients and methods
Patient selection
Eligible patients for this study had histologically diagnosed
breast cancer with documented progressive, bidimensionally
measurable, advanced and/or metastatic disease. All patients
were required to be aged 75 years or younger, to have a
World Health Organization (WHO) performance status of
less than 2, an expected survival of more than 12 weeks, and
to have adequate bone marrow (leucocyte count of more than
4000 dl-1, absolute granulocyte count of more than
2000 pl-', and platelet count of more than 100 000 ul-1),
renal (serum creatinine level of less than 1.5 mg dl-'), and
liver functions (total bilirubin level of less than 1.5 mg dl-1,
transaminase levels less than twice the upper limits of
normal). Prior radiation therapy and a maximum of one
prior regimen of palliative chemotherapy with or without
hormonal therapy were allowed. In these patients, prior
therapy must have been completed at least 4 weeks before
study entry with full resolution of toxicities. All patients gave
informed consent according to institutional regulations.
Patients with metastatic disease that is limited to the bone,
patients with CNS metastases, and those with a prior or a
second coexisting invasive malignancy, were excluded.
Pretreatment andfollow-up evaluation
Pretreatment evaluation included a complete medical history
with documentation of prior therapies and hormone receptor
status, and physical examination with measurement of all
tumour-associated lesions. Laboratory evaluation consisted
of a complete blood cell count with platelet count and
leucocyte differential (WBC) count, an 18-function biochem-
ical profile, prothrombin and partial thromboplastin time,
fibrinogen, and assays of the markers, carcinoembryonic
antigen, CA 15-3 and CA 125. Imaging procedures included
chest radiograph, bone scans, skeletal bone survey and
computerised tomography (CT) plus ultrasound of the
abdomen. Complete blood cell counts and differential counts
were performed weekly, biochemical profiles and tumour
markers were assessed before each treatment cycle. Radio-
graphs or scans of areas of disease were evaluated after every
two treatment courses.
Treatment protocol
Therapy consisted of vinorelbine 50 mg m-2 in 250 ml saline,
infused over 30 min every 3 weeks, and mitomycin C
15 mg m-2 administered by intravenous bolus injection
every 6 weeks. In addition, G-CSF was given at
5 pug kg-' day-1 subcutaneously from days 2 to 7 following
each cytotoxic drug administration. On account of three
severe (WHO grade 3) neurotoxic events among the first 36
patients entered in the study, the dose level of vinorelbine
was reduced to 40 mg m-2 in the subsequent cohort of
patients. Treatment was continued in patients achieving
complete response (CR), partial response (PR) or stable
disease for a total of six courses. Concomitant medications
routinely administered before cytotoxic drug administration
included 8 mg ondansetron and 8 mg dexamethasone.
Toxicity and dosage modification guidelines
Adverse reactions were evaluated according to the WHO
criteria (Miller et al., 1981). Drug doses were reduced by 25%
in subsequent cycles if the lowest WBC (absolute granulo-
cyte) count was less than 1000 pl-' (500 p1l-1), the lowest
platelet count was less than 50 000 1l-', or if any severe (i.e.
>WHO grade 3) non-haematological toxicity was observed
in the previous cycle. Vinorelbine was to be discontinued if a
patient had progressive peripheral neuropathy or had
experienced other severe neurotoxicity. Treatment could be
delayed for up to 2 weeks if the WBC count was lower than
3000 pl-' and/or the platelet count lower than 75 000 pl-'.
Prolonged administration of G-CSF was recommended in the
former group of patients. Any patient who required more
than 2 weeks for haematological recovery was taken off the
study.
Assessment of response
A CR required the complete disappearance of all objective
evidence of disease on two separate measurements at least 4
weeks apart. A PR was defined as a more than 50%
reduction in the sum of the products of the perpendicular
diameters of measurable bidimensional lesions without a CR,
no progression of any lesion by more than 25% or the
appearance of any new lesion, confirmed on two separate
measurements that were 4 weeks apart. In case of bone
metastases, CR was attributed only when there was complete
disappearance of all lesions on radiograph, and PR was
attributed when decrease in size and/or recalcification of lytic
lesions occurred. Decreased density of blastic lesions or
improvement in bone scan-positive, radiograph-negative
disease were not taken into account. Progressive disease
(PD) was defined as the enlargement of any existing
measurable lesion by more than 25% or the development
of new metastatic lesions. Stable disease (SD) was any
measurement that did not fulfil the criteria for PR or PD.
The duration of response was measured from the onset of the
best response to the date of disease progression. The duration
of survival was measured from the time of study entry until
the date of death. All tumour measurements in patients who
responded were reviewed and confirmed by at least two
principal investigators. Confidence intervals (95%) were
calculated as previously described (Anderson et al., 1982).
Results
Patient characteristics
Between October 1992 and July 1994, a total of 55 patients
entered this trial, all of whom were considered evaluable for
response and toxicity assessment. The demographic data,
sites of metastatic tumour, and prior therapies are listed in
Table I. The median age was 59 years (range, 35-75 years),
and the median WHO performance status was 1 (range, 0-
1). Nine patients had locally advanced disease, and 46 had
distant metastases with predominant visceral, bone and soft-
tissue sites in 31, nine and six patients, respectively. Eighteen
patients had received hormonal therapy for advanced disease,
and palliative first-line chemotherapy was given to 14 women.
Previous chemotherapy consisted of cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) variants in fourVinorelbine, mitomycin C, G-CSF in breast cancer
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patients, amonafide-monotherapy (Scheithauer et al., 1991;
Kornek et al., 1994) in one patient, and anthracycline-
containing regimens in nine patients. A total of 178 courses
were administered to the 55 patients. The median number of
treatment cycles was three (range, 1 -6), and the median
duration of follow-up at the time of this analysis was 20
months (range, 12-33 months).
Response to therapy
Anti-tumour responses according to extent of disease (locally
advanced vs metastatic breast cancer) and pretreatment status
are shown in Table II. The overall response rate was 73% for
all 55 patients (95% confidence interval, 59-84%), including
Table I Patient characteristics
Entered/evaluable
Age (years)
Median
Range
Performance status
WHO 0
WHO 1
Disease-free interval (months)
Median
Range
Menopausal status
Premenopause
Post-menopause
Oestrogen receptor status
Positive
Negative
Unknown
Dominant disease site
Viscera
Bone
Soft tissue
Number of organ systems involved
2
>3
Prior therapy
Hormone therapy
Adjuvant
For metastatic disease
Chemotherapy
Adjuvant
For metastatic disease
Anthracyclines
Other
Number ofpatients
55
59
35-75
19
36
13
0-148
13
42
32
17
6
31
9
15
25
21
9
21
18
22
14
9
5
12 CR (22%) and 28 PR (51%). Thirteen patients (24%)
showed stabilisation of disease lasting more than 3 months,
and in only two patients (4%) was the disease progression
not influenced by chemotherapy. The median time to
response for all patients was 2 months (range, 0.8 -5.5
months). The median duration of response in all patients with
metastatic disease was 9.5 months (range, 3.0-22+ months),
and the median time to treatment failure was 10 months, with
a range of 2-24+ months.
All nine patients with locally advanced disease [the median
maximum tumour diameter was 6 cm (range, 3-11 cm), and
six (75%) had clinically involved axillary nodes] were rated
responsive after a median of 1.6 months (range, 0.8-4.0
months) and underwent curative surgery, except one woman
who refused mastectomy. Two patients who presented with a
T3 tumour at study entry, achieved a pathological CR.
Tumours regressed from T3/4 to TI in four patients, and
from T4 to T2 in three patients. At the time of surgery, four
patients had axillary lymph node involvement. Three
premenopausal patients continued with this regimen post-
operatively for another two or three courses, and three post-
menopausal, hormone receptor-positive patients received
adjuvant hormonotherapy with tamoxifen. Only one of the
eight patients who underwent primary neoadjuvant che-
motherapy followed by surgical excision of the residual
tumour (bed) developed (supraclavicular lymph node)
recurrence 11.5 months after initiation of therapy, and the
ninth patient, who refused surgery, died of systemic disease
progression 13 months after study entry. It must be noted
that the median follow-up time in these patients is short at 18
months (range, 13.5-28.0 months).
Among the 32 chemotherapeutically naive patients with
metastatic disease, nine women (28%) achieved CR and 15
(47%) PR. The predominant site of tumour development in
patients who experienced CR was visceral (56%), soft tissue
(33%) and bone (11%); five patients had multiple lesions and
four patients had single metastatic organ sites. Eleven of 15
patients (73%) who achieved PR had multiple metastases
with predominant visceral (60%), bone (20%) and soft-tissue
(20%) disease. The median duration of response in previously
untreated patients with disseminated disease was 10.8 months
(range 3.5 -22 +months), and median time to progression
was 12.0 months (range 2-24+ months).
Among the 14 patients who had received prior palliative
chemotherapy (including nine patients who had received
anthracyclines), seven (50%) responded (one CR, six PR), six
had SD, and tumour progressed in one. The patient with
advanced refractory disease who achieved complete regres-
sion of cervical lymph node metastasis had failed previous
chemotherapy with epirubicin plus cyclophosphamide. Three
of six patients who achieved PR had multiple lesions with
predominant visceral (67%) and bone (33%) metastases, and
five had received previous first-line anthracycline-containing
regimens. Median duration of response in chemotherapeuti-
Table II Objective response related to stage and prior therapy
Patients with
Patients with metastatic disease (%) locally advanced
No prior chemotherapy Pretreated breast carcinoma (%)
(n =32) (n =14) (n =9)
Complete remission 9 (28) 1 (7) 2 (22)
Partial remission 15 (47) 6 (43) 7 (78)
No change 7 (22) 6 (43) 0 (0)
Progression 1 (3) 1 (3) 0 (0)
Overall response rate 24 (75) 7 (50) 9 (100)
Median time to response (months) 2.0 2.2 1.6
Median response duration (months) 10.8 4.5
Median time to progression 12.0 6.0
Median survival (months) >15.5 11.5 18.0Vinorelbine, mitomycin C, G-CSF in breast cancer
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cally pretreated patients was 4.5 months (range 3- 15
months), and median time to progression was 6.0 months
(range, 2-22 months).
It seems n'oteworthy that the response activity of the
treatment regimen was not affected by the dose reduction of
vinorelbine from 50 mg m-2 to 40 mg m-2, which was
performed because of three severe neurotoxic events among
the first 36 patients accrued to the study. The overall
response rates were 72% (26/36 patients; 22% CRs and
50% PRs) and 74% (14/19 patients; 21% CRs and 53% PRs)
for those who were treated at the 50 mg m-2 and 40 mg m-2
dose level respectively.
Toxicity
All 55 patients, who received a total of 178 cycles of therapy
(356 administrations of vinorelbine), were assessable for
toxicity. Side-effects associated with treatment are listed in
Tables III and IV. The dose-limiting toxicity was myelosup-
pression. Leucopenia occurred in 36 patients (65%), and was
grade 3 or 4 in 14 patients (25%). The median nadir WBC
count was 4700 MI`' (range 450-18 500 hl-1) and was
generally observed between day 7 and day 14. The time to
WBC count recovery to more than 3000 pl-1 was short, i.e.
94% of episodes of leucopenia resolved within 7 days. The
variations in granulocyte counts paralleled those of WBCs;
the median nadir of granulocyte counts was 2396 14' (range
0-12 350 l-1). Thrombocytopenia was common, although
rarely severe; it was noted in a total of 18 patients (33%),
and six patients had grade 3 or 4 (11%). There were no
episodes of bleeding. The median nadir platelet count was
189 000 ul- (range 6000-776 000 l-'), with some evidence
of a cumulative nature of this side-effect. Only two patients
(4%) developed grade 3 anaemia requiring packed RBC
transfusion, whereas mild anaemia was recorded in 32
patients (58%). The median nadir of haemoglobin was
11.4 g dl-' (range 7.2-17.6 g dl-1). Seven patients devel-
oped documented infecton, and three of them required
hospitalisation for sepsis, all of whom recovered after
intravenous antibiotic therapy.
Non-haematological side-effects are listed in Table IV.
Gastrointestinal toxicity was the most frequent non-
haematological side-effect (67%), although symptoms were
generally mild, confined to the day of drug administration,
and responsive to standard anti-emetic therapy. Chemically
induced phlebitis was observed in 16 patients (29%),
including three severe local reactions caused by extravasa-
tion of vinorelbine (n =2) or mitomycin C (n = 1); two of
these patients required surgical intervention. Twelve patients
(22%) developed peripheral neurotoxicity. Minor to moder-
ate paraesthesias or decreased tendon reflexes (grade 1 or 2)
occurred in nine patients (16%), whereas three patients were
taken off study owing to severe (grade 3) neurotoxic events:
one patient experienced amaurosis for 24 h, one patient
showed marked motor loss of the lower extremities with full
recovery after 4 h, and one patient reported a painful lockjaw
lasting for almost 3 days. Constipation was observed in 20
patients (36%), and was rated grade 3 in five (9%). A total of
14 patients (25%) developed transient acute respiratory
symptoms resembling an allergic reaction with bronchos-
Table III Highest grade of haematological toxicity experienced
(n=55)
Number ofpatients (%) with toxic effects
of WHO
pasm during or shortly after administration of vinorelbine
(usually on day 21 of their second, third or fourth treatment
course). In six patients respiratory symptoms were rated
severe, although the condition promptly responded to
bronchodilators with or without glucocorticoids. One
woman with subacute onset of symptoms, however, required
respirator support for 18 h. A CT scan disclosed bilateral
interstitial infiltrates, which also fully recovered after
treatment with steroids. None of the patients experiencing
respiratory symptoms had received any other drug with
known pulmonary toxicity and only one each had lung
metastases or other benign pulmonary disease, i.e. chronic
obstructive lung disease. Uncommon severe non-myelosup-
pressive toxicities included mucositis in three patients (5%),
diarrhoea in one patient (2%), and alopecia in five patients
(9%). There was no G-CSF-related toxicity recorded in our
trial, and there were no treatment-related deaths.
Eleven patients (20%) had at least one treatment delay of
1 week at some time during therapy, and the total number of
delayed courses was 16 (9%). The reasons for delayed courses
were haematological in ten patients, non-haematological in
four patients, and personal reasons in two patients.
Seventeen patients (31%) had a 25% dose reduction of
cytotoxic drugs during treatment according to the study
protocol, because of severe haematological (n=7) or other
systemic toxicities (n =6), or both (n =4). A total of 13
patients discontinued treatment as a result of occurrence of
acute lung toxicity (n =7), progressive or severe neurotoxicity
(n =3), intercurrent septicaemia (n = 1), and negative com-
pliance (n =2).
Survival
As of July 1995, with a median follow-up duration of 20
months (range, 12-33 months), 22 of all 55 patients entered,
and 21 of those with metastatic disease have died: 19 of them
after PD and two (both still in PR) as a consequence of
coincident/intercurrent cardiovascular disorders. A total of 24
patients with distant metastases are still alive with disease,
and 16 had received other oncological treatment (chemother-
apy with or without hormonotherapy) after subsequent PD.
Treatments after progression to vinorelbine, mitomycin C
plus G-CSF were chosen according to the oncologist's
judgement and occasional responses were observed in
patients treated with CMF (two of five patients), doxor-
ubicin-containing regimens (four of nine), and taxol' (one of
two). The median survival duration of patients with
previously untreated metastatic disease has not been reached
yet (>15.5 months), and was 11.5 months in those who had
received prior first-line chemotherapy.
Table IV Highest grade of non-haematological toxicity experienced
(n=55)
Number ofpatients (%) with toxic effects
of WHO
Grade I Grade 2 Grade 3 Grade 4
Nausea/vomiting 9 (16) 23 (42) 4 (7)
Diarrhoea 1 (2) 4 (7) 1 (2)
Stomatitis 8 (15) 7 (13) 3 (5)
Alopecia 20 (36) 11(20) 5 (9)
Infection 2 (4) 1 (2) 3 (5) 1 (2)
Phlebitis 7 (13) 6 (11) 3 (5)
Neurotoxicity
Peripheral 5 (9) 4 (7) 3 (5)
CNS 4 (7) 1 (2)
Constipation 8 (15) 7 (13) 5 (9)
Myalgia 1 (2)
Pulmonary toxicity 3 (5) 5 (9) 5 (9) 1 (2)
Anorexia 13 (24) 1 (2)
Liver toxicity 2 (4)
Grade 1 Grade 2 Grade 3 Grade 4
Leucopenia 10 (18) 12 (22) 6 (11) 8 (14)
Neutropenia 7 (13) 6 (11) 10 (18) 9 (16)
Thrombocytopenia 10 (18) 2 (4) 4 (7) 2 (4)
Anaemia 23 (42) 9 (16) 2 (4)Vinorelbine, mitomycin C, G-CSF in breast cancer
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Discussion
In recent times, no major improvements have been achieved
in the treatment of advanced breast cancer (Clavel and
Catimel, 1993). Conventional chemotherapy in this disease is
reported to result in a 37-82% remission rate. Regimens that
contain doxorubicin or its functional and structural
analogues may be slightly better than those that do not,
but the clinical impact of this is limited, taking into account
that metastatic breast cancer has remained an incurable
disease. Preliminary experience with administration of high
doses of chemotherapy with or without autologous bone
marrow transplantation or peripheral stem cell transplanta-
tion is- encouraging (Ayash et al., 1994). These results,
however, are achieved at the expense of major toxic effects
and are necessarely associated with some degree of patient
selection. Thus, it seems unlikely that this approach will be of
benefit in the near future for the large majority of patients
with metastatic disease. Research into new agents and novel
combinations capable of achieving greater response rates with
acceptable toxicity remains a priority.
Based on the results of phase II studies that found
vinorelbine to be an active and tolerable drug in breast
cancer (Cannabbio et al., 1989; Garcia-Conde et al., 1992;
Romero et al., 1994; Toussaint et al., 1994; Fumoleau et al.,
1994), substantial activity for combination chemotherapy
including this agent would be anticipated. Among several
different such combination regimens that have been
investigated in advanced breast cancer (Spielmann et al.,
1994; Fabi et al., 1995; Nole et al., 1995), the combination of
vinorelbine and doxorubicin has shown the most promising
activity, although there was a relative high rate of
cardiotoxicity (10%) resulting in three (4%) treatment-
associated toxic deaths (Spielmann et al., 1994).
In the present study, we report the first results of front-line
chemotherapy of advanced breast cancer with a combination
of vinorelbine and the anti-tumour antibiotic mitomycin C.
The rationale for this combination was the different
mechanism of action (Mangeney et al., 1979; Den Hartig et
al., 1985), resulting in a synergistic effect in vitro (Pouillart et
al., 1974), which could be confirmed clinically in a previous
phase II trial in breast cancer patients with advanced
refractory disease (Scheithauer et al., 1993). According to
the minimal neurotoxicity and occurrence of other systemic
adverse reactions in this trial using conventional vinorelbine
doses, and because myelosuppression constitutes the dose-
limiting toxicity of both drugs (Hohneker, 1994; Hortobagyi,
1993) (which might be overcome by use of a supportive
cytokine), we have investigated a dose-intensified, potentially
more effective treatment schedule that included prophylactic
administration of G-CSF.
Our results suggest an excellent anti-tumour activity,
probably superior to most other available combination
chemotherapy regimens, with an overall response rate of
73% for all patients (95% confidence interval, 59-84%) and
a CR rate of 22%. Nine of nine (100%) patients with locally
advanced disease, twenty-four of 32 (80%) patients with
disseminated disease who had not received previous
chemotherapy, and 7/14 (50%) failing previous palliative
chemotherapy achieved objective remissions within a median
time of only 8 weeks. In patients with metastatic disease, it
seems noteworthy that the effectiveness was not influenced by
the extent of disease (63% of responding patients had
multiple tumour sites), or predominant visceral disease
(58% of responses), i.e. factors that have previously been
demonstrated to be related to adverse and poor outcome
(Falkson et al., 1991). The responses achieved were durable,
with a median response duration for the entire study
population of 9.5 months, and median survival has still not
been reached with a median duration of follow-up of 20
months.
Granulocytopenia was the most frequent and dose-limiting
toxicity of this regimen, although it was generally mild to
moderate, always rapidly reversible, and rarely associated
with infectious complications. Thrombocytopenia was rela-
tively common, and observed in one-third of our patients at
some time during therapy. There were no episodes of
bleeding, however, and according to the cumulative nature
of this side-effect, recurrent severe thrombocytopenia could
be avoided in all seven patients experiencing grade 3 to 4 by
dose and/or interval adjustments during subsequent courses.
Vinorelbine-associated neurological toxicity mainly mani-
fested as paraesthesia, hypoaesthesia or autonomic neuro-
pathy causing constipation. Its overall incidence was similar
to single-agent or combination regimens using conventional
doses of vinorelbine (Hohneker, 1994); severe neurotoxicity
requiring discontinuation of therapy (three patients) was only
observed among those treated at the 50 mg m-2 vinorelbine
dose level, and did not occur after reducing the drug dose to
40 mg m-2 in the subsequent cohort of patients. Respiratory
reactions, characterised by abrupt onset of shortness of
breath during or shortly after vinorelbine administration,
have been reported previously in approximately 5% of
patients treated with this semi-synthetic vinca alkaloid
(Hohneker, 1994). Co-administration of mitomycin, which
may enhance pulmonary toxicity of (natural) vinca alkaloids
(Luedke et al., 1985), and/or use of higher single doses of
vinorelbine may explain the rather common occurrence of
this adverse reaction. In the large majority of our affected
patients, respiratory symptoms were acute in onset, and
resembled an allergic reaction with bronchospasm, promptly
responding to bronchodilators with or without glucocorti-
coids. In one patient, however, it manifested subacutely as
cough and dyspnoea, and was rated grade 4. Complete
resolution of symptoms and CT-documented bilateral
interstitial infiltrates was achieved by steroids in this patient
also. Since this patient had experienced minor acute
respiratory symptoms during the previous cycle, occurrence
of this life-threatening condition might have been preven-
table. All other non-haematological toxicities (vomiting,
diarrhoea, mucositis and hair loss) were of mild to moderate
intensity and were recorded only in a minority of patients.
In conclusion, the results of our study indicate that
vinorelbine, mitomycin C plus G-CSF has an excellent anti-
tumour activity in advanced breast cancer. Therapeutic
results, in fact, compare very favourably with the best
results obtained with other standard regimens. An important
additional advantage of this combination is its apparent non-
cross-resistance with anthracyclines, as indicated both by
objective responses in anthracycline-pretreated patients and
anthracycline-induced remissions after progression to vinor-
elbine, mitomycin C plus G-CSF. Overall toxicity was
moderate with myelosuppression being the dose-limiting
side-effect. Severe non-haematological adverse reactions were
relatively uncommon, and most of them, including constipa-
tion, local toxicity and (sub)acute lung toxicity, might be
avoided by intensified individual concomitant medications,
careful drug administration plus shortening of the infusion
time (Hohneker, 1994), as well as clinical monitoring of all
patients for acute respiratory symptoms during drug
administration.
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